What’s next for the Cochlear share price? A recent update from leading fund manager Wilson Asset Management (WAM) said that “recent data points suggest Cochlear continues to benefit from market share gains as a result of competitor Advanced Bionics … announcing a recall of some of its cochlear implant devices in February 2020”. “Additionally, Cochlear remains a clear winner of the reopening trade and recent feedback from US audiologists suggest cochlear implant patient numbers are strongly above pre-coronavirus levels”. The commentary from WAM bodes well with the solid year-to-date performance of the Cochlear share price. Should you invest $1,000 in Cochlear right now?